Metformin HCL ER
ID: SPE2D2-23-D-0008Type: Special Notice
Overview

Buyer

DEPT OF DEFENSEDEFENSE LOGISTICS AGENCYDLA TROOP SUPPORTPHILADELPHIA, PA, 19111, USA

PSC

DRUGS AND BIOLOGICALS (6505)

Original Source

https://sam.gov/opp/f29923ee78c24d5ca99ae10b5174bcc6/view
Timeline
    Description

    Special Notice DEPT OF DEFENSE DEFENSE LOGISTICS AGENCY is procuring Metformin HCL ER. Metformin HCL ER is a drug used to treat type 2 diabetes. This procurement is being conducted by DLA TROOP SUPPORT. For more information, contact Christopher Newman at christopher.newman@dla.mil or 2157372905.

    Files
    Title
    Posted
    Metformin Award SPE2D223D0008 Final BILATERLLY signed.pdf
    Lifecycle
    Title
    Type
    Metformin HCL ER
    Currently viewing
    Special Notice
    Similar Opportunities
    Metformin HCL
    Buyer not available
    Presolicitation DEPT OF DEFENSE DEFENSE LOGISTICS AGENCY is planning to issue a national requirements contract for Metformin HCL ER. The contract will establish a national supply source to provide Metformin HCL ER Tablets in various quantities and bottle sizes. This will be an unrestricted and fully competitive acquisition. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The items will be purchased by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers through the DLA and VA prime vendor programs. The solicitation will be posted on DLA Bid Board System (DIBBS) and Sam.gov. Interested parties should contact Christopher Newman for any questions/comments. The projected solicitation date is August 2021.
    Dimethyl Fumarate DR Presolicitation
    Buyer not available
    The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Dimethyl Fumarate DR capsules, specifically 120MG capsules in 14 count bottles and 240MG capsules in 60 count bottles. This procurement aims to establish a reliable national supply source for these pharmaceutical products, which are essential for Department of Defense (DoD) customers through the DLA prime vendor program. The contract will be a firm-fixed price, requirements type contract with a one-year base period and four one-year options, emphasizing compliance with federal regulations and efficient distribution of pharmaceuticals for military healthcare. Interested parties should contact Kevin Rafferty at kevin.rafferty@dla.mil or 215-737-0907 for further inquiries, and the projected solicitation date is February 2021, with an amendment extending the offer submission deadline to October 14, 2021, at 3:00 PM EST.
    Sertraline Tablets
    Buyer not available
    The Department of Defense, through the Defense Logistics Agency (DLA) Troop Support, is soliciting offers for the procurement of Sertraline Tablets in 25MG, 50MG, and 100MG dosages, with various bottle counts required over a base year and four option years. This solicitation, identified as SPE2D2-26-R-0002, emphasizes the importance of these pharmaceuticals in supporting military personnel's health and well-being. Interested contractors must submit their proposals electronically via the Defense Logistics Agency Internet Bid Board System (DIBBS) by December 10, 2025, at 3:00 PM EST, and adhere to specific contractual obligations, including a subcontracting plan and compliance with various FAR and DFARS clauses. For further inquiries, potential bidders can contact Christopher Newman at christopher.newman@dla.mil or Jason Wray at jason.wray@dla.mil.
    Metaxalone Tablets
    Buyer not available
    The Department of Defense, through the Defense Logistics Agency (DLA) Troop Support, is soliciting proposals for the supply of Metaxalone 800 MG tablets, available in both 100-count and 500-count bottles. This procurement aims to establish a requirements contract with estimated annual quantities for a base year and four option years, emphasizing the need for compliance with various federal regulations and the submission of a subcontracting plan for large businesses. Metaxalone is a critical medication used for muscle relaxation, highlighting the importance of reliable supply for military personnel. Interested vendors must submit their proposals electronically via the Defense Logistics Agency Internet Bid Board System (DIBBS) between November 7 and December 7, 2025, at 3:00 PM EST, and can reach out to Jeremy Brown or Jason Wray for further inquiries.
    Rabeprazole Sodium Delayed Release Tablets
    Buyer not available
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Rabeprazole Sodium Delayed Release Tablets. The tablets will be used for medical purposes and will be available in 30, 90, and 500 count bottles. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The contract aims to establish a national supply source to provide the tablets for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. Interested parties should contact Phyllis Daraio for more information. The projected solicitation date is February 2020.
    6505--Dimethyl Fumarate Capsules
    Buyer not available
    The Department of Veterans Affairs (VA) is seeking offers for the procurement of Dimethyl Fumarate Capsules (120MG and 240MG delayed-release) through solicitation 36E79726R0003. This contract aims to establish a reliable supply source for these pharmaceutical products to support VA, Department of Defense (DoD), Indian Health Service (IHS), and Bureau of Prisons (BOP) facilities, with a contract structure that includes a one-year base ordering period and four one-year options. The products are critical for treating specific medical conditions, and offerors must comply with stringent requirements, including FDA regulations, Drug Supply Chain Security Act (DSCSA) compliance, and the provision of unique National Drug Codes (NDCs). The deadline for submitting offers has been extended to December 9, 2025, at 2:30 PM CST, and interested parties can contact Contract Specialist Kenneth Lay at Kenneth.Lay@va.gov for further information.
    Ondansetron Orally Disintegrating Tablets
    Buyer not available
    The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Ondansetron Orally Disintegrating Tablets (ODT), specifically 4 MG and 8 MG tablets in various count bottles. This procurement aims to establish a national supply source for these pharmaceutical products, which are critical for treating nausea and vomiting in patients, and will be available for purchase by the Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options, and is expected to be solicited in September 2025, although the DLA reserves the right to issue it earlier or later. Interested parties should direct inquiries to Nancy Fernandez at nancy.fernandez@dla.mil or call 445-737-0713, and are encouraged to set up automated notifications for any changes to the solicitation through the DLA Bid Board System and Sam.Gov.
    Ibuprofen 400MG/600MG/800MG Tablets
    Buyer not available
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Ibuprofen 400MG/600MG/800MG Tablets. The contract will establish a national supply source to provide the items for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. Interested parties should contact Christopher Newman for any questions/comments. The projected solicitation date is March of 2023.
    VISN 21 Lenalidomide Capsules Multiple Strengths (Generic)
    Buyer not available
    The Department of Veterans Affairs (VA) is conducting a Sources Sought notice to identify vendors capable of supplying Lenalidomide Capsules in multiple strengths, specifically for VISN 21, which includes locations in California, Hawaii, Nevada, and Manila, Philippines. The contractor must be a Certified Lenalidomide REMS Pharmacy, licensed in the applicable states, and comply with all relevant federal, state, and VA regulations, including USP <800> for hazardous drugs. This procurement is critical as Lenalidomide is an oral anti-cancer medication, and the contract will span five one-year ordering periods from March 1, 2026, to February 28, 2031, requiring timely and compliant delivery of FDA-approved products. Interested vendors should submit their capability statements and relevant information to David J. Alvarez at david.alvarez4@va.gov by 10:00 AM Pacific Time on December 10, 2025.
    6505--Lenalidomide - Brand Name or Generic
    Buyer not available
    The Department of Veterans Affairs is seeking information from vendors regarding the procurement of Lenalidomide, either in brand name or generic form, for the West Texas VA Health Care System. This sources sought notice aims to gather details on various dosages of Lenalidomide capsules to inform future procurement strategies, potentially leading to either competitive bidding or sole source purchases. Lenalidomide is a critical pharmaceutical used in the treatment of certain cancers and conditions, making this procurement essential for patient care within the VA system. Interested vendors must submit a capability statement by December 5, 2025, at 5:00 PM CST, including their technical capabilities and company information, to Contracting Specialist Matt Lee at matthew.lee5@va.gov or by phone at 210-393-9281.